ivabradine (corlanor) Report issue

Small molecule Approved FDA First in Class Fast Track FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Ivabradine (CORLANOR®) is a hyperpolarization-activated cyclic nucleotide-gated channel blocker that reduces the spontaneous pacemaker activity of the cardiac sinus node by selectively inhibiting the If-current, resulting in heart rate reduction at concentrations that do not affect other cardiac ionic currents. Specific heart-rate lowering with ivabradine (CORLANOR®) reduces myocardial oxygen demand, simultaneously improving oxygen supply. It has no negative inotropic or lusitropic effects, preserving ventricular contractility, and does not change any major electrophysiological parameters unrelated to heart rate.   NCATS

Chemistry

  • SMILES: COc1cc2c(cc1OC)CC(=O)N(CCCN(C)C[C@H]1Cc3cc(OC)c(OC)cc31)CC2
  • InChIKey: ACRHBAYQBXXRTO-OAQYLSRUSA-N
  • Mol. Mass: 468.59
  • ALogP: 3.31
  • ChEMBL Molecules:
    ivabradine  
    ivabradine hydrochloride  
More Chemistry

Pharmacology

Drug Pricing (per unit)

Australia

$0.4619

United States

$5.4307 - $7.9354
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

3-[3-({[(7s)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}(methyl)amino)propyl]-7,8-dimethoxy-2,3,4,5-tetrahydro-1h-3-benzazepin-2-one | 7,8-dimethoxy-3-(3-(((4,5-dimethoxybenzocyclobutan-1-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-2h-benzazepin-2-one | amg-998 | coraxan | corlanor | corlentor | ivabradin | ivabradina | ivabradine | ivabradine hcl | ivabradine hydrochloride | ivabradinum | procoralan | s 16257 | s-16257 | s 16257-2 | s-16257-2 | s 16260-2 | s-16260-2

Organizations (91)

Research & Development (86)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (6)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (45)

Approved Indications (1)


 

Heart Failure

Experimental Indications - Clinical Trial Phases 1-4 (45)


 

Acute Coronary Syndrome (Phase 4)

Aging (Phase 3)

Angina Pectoris (Phase 4)

Angina, Stable (Phase 4)

Arterial Pressure (Phase 4)

Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome (Phase 4)

Atrial Fibrillation (Phase 3)

Atrial Remodeling (Phase 4)

Blood Pressure (Phase 4)

Cancer Survivors (Phase 2)

Cardiomyopathy, Dilated (Phase 4)

Cardiovascular Diseases (Phase 4)

Coronary Artery Disease (Phase 4)

Coronary Disease (Phase 4)

Diabetic Nephropathies (Phase 3)

General Surgery (Phase 3)

Healthy Volunteers (Phase 3)

Heart Diseases (Phase 4)

Heart Failure (Phase 4)

Heart Failure, Diastolic (Phase 2)

Heart Failure, Systolic (Phase 4)

Heart Rate (Phase 4)

Heart Transplantation (Phase 4)

Hemodynamics (Phase 4)

Hypotension (Phase 2)

Ivabradine (Phase 4)

Livedoid Vasculopathy (Phase 4)

Lymphoma (Phase 2)

Mitral Valve Stenosis (Phase 3)

Multiple Organ Failure (Phase 2)

Myocardial Ischemia (Phase 4)

Myocardium (Phase 4)

Neoplasms (Phase 3)

Non-ST Elevated Myocardial Infarction (Phase 2/Phase 3)

Post-Acute COVID-19 Syndrome (Phase 4)

Postural Balance (Phase 2)

Postural Orthostatic Tachycardia Syndrome (Phase 4)

Renal Dialysis (Phase 4)

Sepsis (Phase 4)

Shock, Cardiogenic (Phase 4)

Shock, Septic (Phase 3)

Tachycardia (Phase 4)

Vascular Stiffness (Phase 3)

Ventricular Dysfunction, Left (Phase 3)

Ventricular Remodeling (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 77
  • # of Trial Organizations: 86

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue